From Pichia anomala killer toxin through killer antibodies to killer peptides for a comprehensive anti-infective strategy

Antonie van Leeuwenhoek, International Journal of General and Molecular Microbiology

Volumn 99, Issue 1, 2011, Pages 35-41

  Polonelli, Luciano ^a   Magliani, Walter ^a   Ciociola, Tecla ^a   Giovati, Laura ^a   Conti, Stefania ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Anti infective peptides; Antifungal vaccines; Microbicidal antibodies; Pichia anomala; Yeast killer toxin

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BETA 1,3 GLUCAN; BETA GLUCAN; CHEMOKINE RECEPTOR CCR5; FLUCONAZOLE; GLYCOPROTEIN GP 120; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; RECOMBINANT ANTIBODY; YEAST KILLER FACTOR;

ACANTHAMOEBA CASTELLANII; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIMICROBIAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BIOTECHNOLOGY; CANDIDIASIS; CRYPTOCOCCOSIS; CYTOTOXICITY; DENDRITIC CELL; EX VIVO STUDY; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA VIRUS A; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LYMPHOCYTE PROLIFERATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PARACOCCIDIOIDES BRASILIENSIS; PICHIA ANOMALA; PLANT DISEASE; PNEUMOCYSTIS CARINII; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR DOWN REGULATION; SACCHAROMYCES CEREVISIAE; STREPTOCOCCUS GORDONII; TINEA VERSICOLOR; VAGINA CANDIDIASIS; VIRUS REPLICATION;

ANIMALS; ANTI-INFECTIVE AGENTS; BIOLOGICAL PRODUCTS; DENDRITIC CELLS; FEMALE; FUNGAL VACCINES; FUNGI; HUMANS; IMMUNOLOGIC FACTORS; KILLER FACTORS, YEAST; MICE; PICHIA; VIRUSES;

HUMAN IMMUNODEFICIENCY VIRUS 1; INFLUENZA A VIRUS; MURINAE; PICHIA ANOMALA; SACCHAROMYCES CEREVISIAE;

EID: 79451468919     PISSN: 00036072     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10482-010-9496-3     Document Type: Article

References (38)

1. C Beninati MR Oggioni M Boccanera MR Spinosa T Maggi S Conti, et al. 2000 Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria Nat Biotechnol 18 1060 1064 10.1038/80250 1:CAS:528:DC%2BD3cXntlOht7g%3D 10.1038/80250 11017043
2. Bevan EA, Makower M (1963) The physiological basis of the killer character in yeast. In Proc XIth Int Congr Genet, vol 1. Pergamon Press, The Netherlands, pp 202-203
3. C Bromuro A Torosantucci P Chiani S Conti L Polonelli A Cassone 2002 Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a Candida albicans vaccine Infect Immun 70 5462 5470 10.1128/IAI.70.10.5462-5470.2002 1:CAS:528:DC%2BD38XnsV2ls78%3D 10.1128/IAI.70.10.5462-5470.2002 12228271
4. C Casoli E Pilotti CF Perno E Balestra E Polverini A Cassone, et al. 2006 A killer mimotope with therapeutic activity against AIDS-related opportunistic micro-organisms inhibits ex-vivo HIV-1 replication AIDS 20 975 980 10.1097/01.aids.0000222068.14878.0d 10.1097/01.aids.0000222068.14878.0d 16603848
5. E Cenci A Mencacci A Spreca C Montagnoli A Bacci K Perruccio, et al. 2002 Protection of killer antiidiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation Infect Immun 70 2375 2382 10.1128/IAI.70.5.2375-2382.2002 1:CAS:528:DC%2BD38XjtFKgur0%3D 10.1128/IAI.70.5.2375-2382.2002 11953373
6. E Cenci F Bistoni A Mencacci S Perito W Magliani S Conti, et al. 2004 A synthetic peptide as a novel anticryptococcal agent Cell Microbiol 6 953 961 10.1111/j.1462-5822.2004.00413.x 1:CAS:528:DC%2BD2cXnvVart7g%3D 10.1111/j.1462-5822.2004.00413.x 15339270
7. E Cenci E Pericolini A Mencacci S Conti W Magliani F Bistoni, et al. 2006 Modulation of phenotype and function of dendritic cells by a therapeutic synthetic killer peptide J Leukoc Biol 79 0 45 10.1189/jlb.0205113 1:CAS:528:DC%2BD28XlvVSrug%3D%3D
8. S Conti F Fanti W Magliani M Gerloni D Bertolotti A Salati, et al. 1998 Mycobactericidal activity of human natural, monoclonal, and recombinant yeast killer toxin-like antibodies J Infect Dis 177 807 811 1:CAS:528: DyaK1cXhsF2ktL0%3D 10.1086/517815 9498471
9. S Conti W Magliani S Arseni R Frazzi A Salati L Ravanetti L Polonelli 2002 Inhibition by yeast killer toxin-like antibodies of oral Streptococci adhesion to tooth surfaces in an ex vivo model Mol Med 8 313 317 1:CAS:528:DC%2BD38XnvFyjtLc%3D 12428062
10. G Conti W Magliani S Conti L Nencioni R Sgarbanti AT Palamara L Polonelli 2008 Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection Antimicrob Agents Chemother 52 4331 4337 10.1128/AAC.00506-08 1:CAS:528:DC%2BD1cXhsV2murfK 10.1128/AAC.00506-08 18824612
11. S Conti W Magliani L Giovati I Libri DL Maffei A Salati L Polonelli 2008 Screening of a Saccharomyces cerevisiae nonessential gene deletion collection for altered susceptibility to a killer peptide New Microbiol 31 143 145 18437854
12. M Donini C Lico S Baschieri S Conti W Magliani L Polonelli E Benvenuto 2005 Production of an engineered killer peptide in Nicotiana benthamiana by using a potato virus X expression system Appl Environ Microbiol 71 6360 6367 10.1128/AEM.71.10.6360-6367.2005 1:CAS:528:DC%2BD2MXhtFajur7I 10.1128/AEM.71.10.6360-6367.2005 16204558
13. PL Fiori A Mattana D Dessi S Conti W Magliani L Polonelli 2006 In vitro acanthamoebicidal activity of a killer monoclonal antibody and a synthetic peptide J Antimicrob Chemother 57 891 898 10.1093/jac/dkl051 1:CAS:528:DC%2BD28Xjtlams70%3D 10.1093/jac/dkl051 16507561
14. NK Jerne 1974 Towards a network theory of the immune system Ann Immunol (Paris) 125C 373 389 1:STN:280:DyaE2M7mtleitQ%3D%3D
15. WJ Loesche 1986 Role of Streptococcus mutans in human dental decay Microbiol Rev 50 353 380 1:CAS:528:DyaL2sXmsFSrtg%3D%3D 3540569
16. W Magliani S Conti M Gerloni D Bertolotti L Polonelli 1997 Yeast killer systems Clin Microbiol Rev 10 369 400 1:CAS:528:DyaK2sXkvFymt7k%3D 9227858
17. W Magliani S Conti F de Bernardis M Gerloni D Bertolotti P Mozzoni, et al. 1997 Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity Nat Biotechnol 15 155 158 10.1038/nbt0297-155 1:CAS:528:DyaK2sXptFaqsg%3D%3D 10.1038/nbt0297-155 9035141
18. W Magliani S Conti A Salati S Vaccari L Ravanetti DL Maffei L Polonelli 2004 Therapeutic potential of yeast killer toxin-like antibodies and mimotopes FEMS Yeast Res 5 11 18 10.1016/j.femsyr.2004.06.010 1:CAS:528: DC%2BD2cXnslKitL8%3D 10.1016/j.femsyr.2004.06.010 15381118
19. W Magliani S Conti A Salati S Arseni L Ravanetti R Frazzi L Polonelli 2004 Engineered killer mimotopes: new synthetic peptides for antimicrobial therapy Curr Med Chem 11 1793 1800 1:CAS:528:DC%2BD2cXkvFOqsbg%3D 15279582
20. W Magliani S Conti LR Travassos L Polonelli 2008 From yeast killer toxins to antibiobodies and beyond FEMS Microbiol Lett 288 1 8 10.1111/j.1574-6968. 2008.01340.x 1:CAS:528:DC%2BD1cXhtlans7jO 10.1111/j.1574-6968.2008.01340.x 18785931
21. M Manfredi E Merigo A Salati S Conti A Savi L Polonelli, et al. 2007 In vitro candidacidal activity of a synthetic killer decapeptide (KP) against Candida albicans cells adhered to resin acrylic discs J Oral Pathol Med 36 468 471 10.1111/j.1600-0714.2007.00561.x 1:CAS:528:DC%2BD2sXhtVKltbjK 10.1111/j.1600-0714.2007.00561.x 17686004
22. TA Pertinhez S Conti E Ferrari W Magliani A Spisni L Polonelli 2009 Reversible self-assembly: a key feature for a new class of autodelivering therapeutic peptides Mol Pharm 6 1036 1039 10.1021/mp900024z 1:CAS:528:DC%2BD1MXkslOltbw%3D 10.1021/mp900024z 19366260
23. M Pettoello-Mantovani A Nocerino L Polonelli G Morace S Conti L Di Martino, et al. 1995 Hansenula anomala killer toxin induces secretion and severe acute injury in the rat intestine Gastroenterology 109 1900 1906 S0016508595004082 1:CAS:528:DyaK28XlvFalsA%3D%3D 10.1016/0016-5085(95)90757-2 7498655
24. L Polonelli G Morace 1986 Reevaluation of the yeast killer phenomenon J Clin Microbiol 24 866 869 1:STN:280:DyaL2s%2FjsValsQ%3D%3D 3771773
25. L Polonelli G Morace 1987 Production and characterization of yeast killer toxin monoclonal antibodies J Clin Microbiol 25 460 462 1:CAS:528: DyaL2sXhtVSlsrw%3D 2434524
26. L Polonelli R Lorenzini F De Bernardis G Morace 1986 Potential therapeutic effect of yeast killer toxin Mycopathologia 96 103 107 1:CAS:528:DyaL2sXmtVyhsw%3D%3D 10.1007/BF00436668 3796712
27. L Polonelli F Fanti S Conti L Campani M Gerloni M Castagnola, et al. 1990 Detection by immunofluorescent anti-idiotypic antibodies of yeast killer toxin cell wall receptors of Candida albicans J Immunol Methods 132 205 209 1:STN:280:DyaK3M%2FhtVyhsw%3D%3D 10.1016/0022-1759(90)90031-P 2170534
28. L Polonelli S Conti M Gerloni W Magliani M Castagnola G Morace C Chezzi 1991 'Antibiobodies': antibiotic-like anti-idiotypic antibodies J Med Vet Mycol 29 235 242 1:STN:280:DyaK38%2FksFaitg%3D%3D 10.1080/02681219180000351 1941431
29. L Polonelli R Lorenzini F De Bernardis M Gerloni S Conti G Morace, et al. 1993 Idiotypic vaccination: immunoprotection mediated by anti-idiotypic antibodies with antibiotic activity Scand J Immunol 37 105 110 1:CAS:528:DyaK3sXhsVGmt7c%3D 10.1111/j.1365-3083.1993.tb01671.x 8418467
30. L Polonelli F De Bernardis S Conti M Boccanera M Gerloni G Morace, et al. 1994 Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies J Immunol 152 3175 3182 1:CAS:528:DyaK2cXis1OltLo%3D 8144911
31. L Polonelli F De Bernadis S Conti M Boccanera W Magliani M Gerloni, et al. 1996 Human natural yeast killer toxin-like candidacidal antibodies J Immunol 156 1880 1885 1:CAS:528:DyaK28Xht1ejurw%3D 8596040
32. L Polonelli W Magliani S Conti L Bracci L Lozzi P Neri, et al. 2003 Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis Infect Immun 71 6205 6212 1:CAS:528:DC%2BD3sXoslegu7k%3D 10.1128/IAI.71.11.6205-6212.2003 14573638
33. A Rachini D Pietrella P Lupo A Torosantucci P Chiani C Bromuro, et al. 2007 An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo Infect Immun 75 5085 5094 10.1128/IAI.00278-07 1:CAS:528:DC%2BD2sXht1CrtLzO 10.1128/IAI.00278-07 17606600
34. D Savoia S Scutera S Raimondo S Conti W Magliani L Polonelli 2006 Activity of an engineered synthetic killer peptide on Leishmania major and Leishmania infantum promastigotes Exp Parasitol 113 186 192 10.1016/j.exppara. 2006.01.002 1:CAS:528:DC%2BD28Xltlegu7Y%3D 10.1016/j.exppara.2006.01.002 16487518
35. N Seguy L Polonelli E Dei-Cas JC Cailliez 1997 Monoclonal killer toxin-like antiidiotypic antibodies to control rat-pneumocystosis J Eukaryot Microbiol 44 37S 1:CAS:528:DyaK1cXks12qug%3D%3D 10.1111/j.1550-7408.1997. tb05761.x 9508425
36. N Seguy JC Cailliez P Delcourt S Conti D Camus E Dei-Cas L Polonelli 1997 Inhibitory effect of human natural yeast killer toxin-like candidacidal antibodies on Pneumocystis carinii Mol Med 3 544 552 1:CAS:528: DyaK2sXmtl2ktL4%3D 9307982
37. A Torosantucci C Bromuro P Chiani F De Bernardis F Berti C Galli, et al. 2005 A novel glyco-conjugate vaccine against fungal pathogens J Exp Med 202 597 606 10.1084/jem.20050749 1:CAS:528:DC%2BD2MXhtVSjs7zN 10.1084/jem.20050749 16147975
38. LR Travassos LS Silva EG Rodrigues S Conti A Salati W Magliani L Polonelli 2004 Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis J Antimicrob Chemother 54 956 958 10.1093/jac/dkh430 1:CAS:528:DC%2BD2cXhtVSru7vL 10.1093/jac/dkh430 15448128